Pricing Log in Create free account
Saturday 17 October 2026 Export TLPH’s income statement to Excel — free account

Talphera, Inc.

TLPH Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.

1.08 0.01 +0.93%
Market cap
$55.5M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
n/a
Altman Z
−20.73
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.30
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — 4 1 — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 48.93%

Capital & Financial Ratios $m

Market Cap 55.54
Revenue 0.43
Net Income (15.08)
Free Cash Flow (12.27)
Net Debt (17.08)
Current Ratio 4.29 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (3.10) (negative: loss-making)
P/S ratio 191.48 (above 10: high)
P/B ratio 5.66
Past 5Y EPS Growth —
This Y EPS Growth 41.18% (at or above 15%: strong)
Next Y EPS Growth (5.00%) (below 0%: weak)
Next Y revenue growth 1,496.43% (at or above 10%: strong)
Next 5Y EPS Growth 28.04% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 166×, against a ten-year median of 17.5×; over the ten years it ranged from −1.1× in 2023 to 202× in 2026.
P/S against its own 10 years 97.57%
10-year low 10-year high
P/B against its own 10 years 77.60%
10-year low 10-year high
EV/Sales against its own 10 years 97.53%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 9 9 20 17
Receivables — — — —
Inventory — — — —
Other — — — —
12 9 21 18
2023 2024 2025 Q'26
Payables 1 1 1 0
ST’ Debt — — — —
Other — — — —
5 3 4 4

Compound Annual Growth %

10y 5y 3y
Sales (40.71%) (58.55%) (78.50%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (6.43%) 0.00% (7.91%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 0 — 0 — 0
’23 — 0 0 0 1
’22 0 1 1 0 2
’21 1 0 2 0 3
’20 0 3 1 1 5
’19 0 1 1 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (4) — — —
’25 (3) (3) (3) (2) (11)
’24 (3) (5) (3) (2) (13)
’23 (5) (5) (3) (4) (17)
’22 (9) (9) (5) (5) (28)
’21 (10) (8) (4) (8) (30)
’20 (14) (10) (8) (6) (39)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (4) — — —
’25 (3) (3) (3) (2) (11)
’24 (3) (5) (3) (2) (13)
’23 (5) (3) (3) (4) (15)
’22 (9) (9) (5) (7) (30)
’21 (10) (10) (4) (8) (32)
’20 (14) (10) (8) (8) (40)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.04) (0.06) — — —
’25 (0.10) (0.10) (0.11) (0.06) (0.34)
’24 (0.16) (0.15) (0.13) (0.07) (0.50)
’23 (0.75) (0.40) (0.08) (0.25) (1.29)
’22 (1.20) 9.60 (0.94) (1.00) 5.72
’21 (1.60) (1.60) (1.40) (1.20) (5.80)
’20 (4.00) (1.60) (2.00) (2.00) (9.40)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 48.00 31.00 33.00 32.80 14.00 9.20 1.76 0.43 0.50 0.38

Analyst estimates 2026–2028

Powerpack
High 90.00 115.00 101.00 81.80 42.80 58.80 13.00 2.78 1.61 1.57
People
People Employees 39 41 61 99 54 43 19 15 13 12
Revenue/emp, $m 0.45 0.20 0.04 0.02 0.10 0.07 0.09 0.04 0.00 0.00
Income, $m
Income, $m Revenue 17 8 2 2 5 3 2 1 — 0
Gross margin, % 29.05 (33.32) (84.84) (197.34) (11.37) (33.18) (46.30) 100.00 — 100.00
EBT (43) (52) (47) (53) (40) (35) 59 (10) (13) (14)
EBT margin, % (248.84) (653.02) (2,191.86) (2,325.78) (745.48) (1,245.35) 3,339.24 (1,580.18) 0.00 (51,296.43)
Net income (43) (52) (47) (53) (40) (35) 48 (18) (13) (14)
Depreciation 2 2 1 2 2 2 2 0 0 0
Per share, $
Per share, $ Revenue 7.66 3.41 0.74 0.58 1.27 0.47 0.24 0.05 0.00 0.00
Earnings (19.00) (22.00) (16.20) (13.40) (9.40) (5.80) 5.73 (1.29) (0.50) (0.34)
Cash flow (12.97) (12.70) (9.96) (12.93) (9.03) (5.01) (3.84) (1.23) (0.49) (0.27)
Capex (1.64) (1.03) (0.28) (0.88) (0.44) (0.30) (0.28) 0.18 0.00 0.00
Free cash flow (14.62) (13.72) (10.24) (13.80) (9.47) (5.31) (4.11) (1.04) (0.49) (0.27)
Book value (2.36) (15.57) 1.46 (10.46) (13.08) (5.99) 2.95 0.99 0.31 0.40
Shares, m 2 2 3 4 4 6 7 14 26 42
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.00 — 0.00
P/S 6.66 12.02 62.73 72.99 19.52 23.82 9.26 11.69 — 113.49
P/B 0.00 0.00 31.73 0.00 0.00 0.00 0.75 0.75 — 2.84
EV/Sales 3.27 6.85 19.16 55.08 15.64 12.17 2.27 8.34 — 80.58
EV/FCF (1.71) (1.70) (1.38) (2.31) (2.10) (1.08) (0.13) (0.51) — (3.93)
Cash, $m
Cash, $m Operating cash flow (29) (30) (29) (51) (39) (30) (28) (17) (13) (11)
Capex (4) (2) (1) (3) (2) (2) (2) 3 — —
Free cash flow (33) (32) (30) (55) (40) (32) (30) (15) (13) (11)
Balance, $m
Balance, $m Working capital 79 50 92 58 29 32 11 7 7 17
Total debt 22 19 12 25 22 14 5 — — —
Net debt (59) (41) (94) (41) (21) (33) (15) (9) (9) (20)
Shareholders’ equity (5) (37) 4 (41) (56) (36) 22 14 8 17
Returns, %
Returns, % ROA (37.89) (58.68) (48.09) (50.25) (51.23) (48.69) 67.52 (54.20) (67.32) (59.60)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (246.80) (223.45) 0.00 0.00
ROE (310.75) 246.18 292.34 286.51 83.11 76.60 (601.31) (102.44) (117.65) (114.16)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2025

Charts ten years each

Talphera, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CLVR Clever Leaves Holdings Inc. $96.5M — (loss-making) — (loss-making) +5.36% (above 0%: growing) n/m +70.31% (above 0%: growing) (7.46%) (105.91%) Compare
CTOR Citius Oncology, Inc. $69.4M — (loss-making) — — n/m 0.00% 67.07% (583.53%) Compare
TLPH Talphera, Inc. $55.5M — (loss-making) — (loss-making) −99.60% (below 0%: shrinking) n/m −33.11% (below 0%: shrinking) 100.00% 0.00%
INCR InterCure Ltd. $55.1M 8.8× — (loss-making) −6.53% (below 0%: shrinking) n/m +389.50% (above 0%: growing) 32.04% 0.00% Compare
ZYBT Zhengye Biotechnology Holding Limited $44.6M — — — — −69.31% (below 0%: shrinking) — — Compare
SCYX SCYNEXIS, Inc. $38.9M — (loss-making) — (loss-making) −8.56% (below 0%: shrinking) n/m −98.60% (below 0%: shrinking) 100.00% (3,308.51%) Compare
IXHL Incannex Healthcare Inc. $36.1M — (loss-making) — (loss-making) −92.31% (below 0%: shrinking) n/m +327.73% (above 0%: growing) 100.00% 0.00% Compare
RMTI Rockwell Medical, Inc. $32.2M — (loss-making) — (loss-making) +10.63% (above 0%: growing) n/m −12.92% (below 0%: shrinking) 18.24% (5.97%) Compare
CPHI China Pharma Holdings, Inc. $31.3M — (loss-making) — (loss-making) −7.56% (below 0%: shrinking) n/m −113.57% (below 0%: shrinking) 8.82% (150.99%) Compare
Median of peers $41.7M — — −7.04% — −6.46% 32.04% (105.91%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Talphera, Inc. (TLPH) key facts

  • Talphera, Inc. (TLPH) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, TLPH traded at $1.08, a market capitalization of $55.5 million.
  • Return on equity was −114.2% and debt-to-equity 0.00.
  • Its Altman Z-score is −20.73 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Talphera, Inc. (TLPH) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/TLPH · Data as of Sep 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com